NCT05914545View on ClinicalTrials.gov

A Study of FZ-AD004 in Patients with Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced and Metastatic Solid Tumor
Interventions
DRUG

FZ-AD004

"Dose Escalation：Subjects will receive an intravenous infusion of FZ-AD004 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.~Dose Expansion：Subject will receive a single dose of FZ-AD004 at 1-2 dose level on Day1 of each cycles."

Trial Locations (1)

Unknown

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

INDUSTRY